Nuvectis Pharma, Inc.
NASDAQ:NVCT
6.67 (USD) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
| Revenue
| 0 | 0.149 | 0 | 0 |
| Cost of Revenue
| 22.897 | 19.234 | 12.894 | 0 |
| Gross Profit
| -22.897 | -19.085 | -12.894 | 0 |
| Gross Profit Ratio
| 0 | -128.087 | 0 | 0 |
| Reseach & Development Expenses
| 15.38 | 13.227 | 9.545 | 0 |
| General & Administrative Expenses
| 7.503 | 6.007 | 3.349 | 0.024 |
| Selling & Marketing Expenses
| 7.509 | 0 | 0 | 0.01 |
| SG&A
| 7.517 | 6.007 | 3.349 | 0.01 |
| Other Expenses
| 0 | 0 | 0 | 0 |
| Operating Expenses
| 22.897 | 19.234 | 12.894 | 0.01 |
| Operating Income
| -22.897 | -19.234 | -12.894 | -0.01 |
| Operating Income Ratio
| 0 | -129.087 | 0 | 0 |
| Total Other Income Expenses Net
| 0.637 | 0.149 | 0.004 | 0 |
| Income Before Tax
| -22.26 | -19.085 | -12.89 | -0.01 |
| Income Before Tax Ratio
| 0 | -128.087 | 0 | 0 |
| Income Tax Expense
| 0.001 | -0.298 | -0.004 | -0 |
| Net Income
| -22.26 | -18.787 | -12.886 | -0.01 |
| Net Income Ratio
| 0 | -126.087 | 0 | 0 |
| EPS
| -1.43 | -1.48 | -1.01 | -0.001 |
| EPS Diluted
| -1.43 | -1.48 | -1.01 | -0.001 |
| EBITDA
| -22.897 | -19.234 | -12.894 | -0.01 |
| EBITDA Ratio
| 0 | -129.087 | 0 | 0 |